Evidence map›Paper›PMID 39979993›Full record

ArticleBMC biotechnology2025

Synergistic antibacterial activity of chitosan-polyethylene glycol nanocomposites films containing ZIF-8 and doxycycline.

Fahimeh Jamiri, Bahar Nayeri Fasaei, Seyed Mehdi Joghataei, Ramak Yahyaraeyat, Azin Mazloom-Jalali

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Pharmacological and Biological Efficacy of Chitosan-Based Materials.International journal of molecular sciences · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fahimeh JamiriDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Bahar Nayeri FasaeiDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran. nayerib@ut.ac.ir.ORCID 0000-0003-2373-4667
Seyed Mehdi JoghataeiDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.ORCID 0000-0002-1572-9473
Ramak YahyaraeyatDepartment of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Azin Mazloom-JalaliDepartment of Chemistry, Amir Kabir University of Technology (Tehran Polytechnic), P.O.Box: 15875-4413, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntibiotic resistance is a growing global threat due to antibiotic overuse and limited treatment options. Multidrug-resistant bacteria, like Staphylococcus aureus and Escherichia coli, increase infection complexity and mortality. This study explores nanocomposite films of ZIF-8 nanoparticles and Doxycycline (Dox) to enhance antibacterial efficacy. In this study, nanocomposite films composed of chitosan (CS) and polyethylene glycol (PEG), incorporating zeolitic imidazolate framework-8 (ZIF-8) nanoparticles and DOX, were developed. These films were characterized by their morphological, mechanical, antibacterial, and drug-release properties. Antibacterial efficacy was evaluated using disk diffusion, broth microdilution, and checkerboard assay methods to determine MICs and potential synergistic effects.

resultsThe nanocomposite films demonstrated flexibility, semi-transparency, and a yellowish-brown hue, with films containing ZIF-8 nanoparticles being thicker (79 ± 0.2 μm) than those without (54 ± 0.5 μm). The tensile strength was enhanced with the incorporation of ZIF-8, peaking at 53.12 MPa for the CS-PEG-G-10% DOX-4% ZIF-8 film. XRD analysis confirmed the crystallinity of the ZIF-8 and DOX, with distinct peaks observed for each material. The drug release studies revealed an initial burst followed by sustained release, with higher release rates in acidic environments compared to neutral and alkaline media. The CS-PEG-G-10% DOX-4% ZIF-8 nanocomposite film demonstrated significantly higher antibacterial activity, achieving the lowest MIC values, particularly against S. aureus (22.5 mm inhibition zone) compared to E. coli (14 mm inhibition zone). Additionally, a notable synergistic effect was observed between CS-PEG-G-10% DOX and CS-PEG-G-10% DOX, with FICI values below 0.5.

conclusionsThe CS-PEG-G-10% DOX-4% ZIF-8 nanocomposite exhibits enhanced antibacterial efficacy and optimal properties, positioning it as a strong candidate for developing effective treatments against multidrug-resistant pathogens.

Indexed as

Anti-Bacterial AgentsChitosanDoxycyclineMetal-Organic FrameworksNanocompositesPolyethylene GlycolsZeolitesDrug LiberationDrug SynergismEscherichia coliImidazolesMicrobial Sensitivity TestsStaphylococcus aureusAnti-Bacterial AgentsChitosanDoxycyclineImidazolesMetal-Organic FrameworksPolyethylene GlycolsZeolitesZIF-8 metal-organic frameworkAntibacterial drugsChitosanDoxycyclineDrug deliveryEscherichia coliMetal-organic frameworksNanocompositesStaphylococcus aureusZIF-8 nanoparticle

Identifiers

PMID39979993
PMCPMC11841006

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.